Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor α-positive eosinophilic leukemia

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 4, 2008, Pages 1054-1056

  Simon, Dagmar ^a   Salemi, Souzan ^b   Yousefi, Shida ^b   Simon, Hans Uwe ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FIP1 LIKE 1 PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA; HYDROCORTISONE; HYDROXYUREA; IMATINIB; MEPOLIZUMAB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIC LEUKEMIA; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LETTER; LOW DRUG DOSE; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHRONIC DISEASE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECOMBINANT FUSION PROTEINS;

EID: 41449117618     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.11.027     Document Type: Letter

References (10)

1. Gleich G.J., Leiferman K.M., Pardanasi A., Tefferi A., and Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359 (2002) 1577-1578
2. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1204
3. Simon H.U., Plötz S.G., Dummer R., and Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 (1999) 1112-1120
4. Simon H.U., Plötz S.G., Simon D., Seitzer U., Braathen L.R., Menz G., et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol 33 (2003) 834-839
5. Klion A.D., Robyn J., Akin C., Noel P., Brown M., Law M., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103 (2004) 473-478
6. Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103 (2004) 2939-2941
7. Yamada Y., Rothenberg M.E., Lee A.W., Akei H.S., Brandt E.B., Williams D.A., et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 107 (2006) 4071-4079
8. Plötz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
9. Nardi V., Azam M., and Daley G.Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 11 (2003) 35-43
10. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of Bcr-Abl. Cell 112 (2003) 831-843